Drugs in the Workplace
- Intro to Workplace Drug Abuse
- A Drug-Free Workplace
- Symptoms and Intervention
- Signs of Drug Abuse
- Helplines for Employees
- Drug-Free Workplaces
- Facts and Figures
- Frequently Asked Questions
- Industries & Economic Sectors
- Substance Abuse Awareness
- Uncovering the Hidden Signs
- Written Policy Statement
- Saving Lives and Money
- Training Supervisors

 




 





Skip Navigation

Dextroproxyphene

A close relative of methadone, dextropropoxyphene was first marketed in 1957 under the trade name of Darvon®. Oral analgesic potency is one-half to one-third that of codeine, with 65 mg approximately equivalent to about 600 mg of aspirin. Dextroproxyphene is prescribed for relief of mild to moderate pain. Bulk dextropropoxyphene is in Schedule II, while preparations containing it are in Schedule IV. More than 100 tons of dextropropoxyphene are produced in the United States annually, and more than 30 million prescriptions are written for the products. This narcotic is associated with a number of toxic side effects and is among the top 10 drugs reported by medical examiners in drug abuse deaths.